Immix Biopharma announces NXC-201 relapsed/refractory AL Amyloidosis data

Immix Biopharma announced new clinical data from its Phase 1b/2a NEXICART-1 study of novel, autologous, sterically-optimized BCMA-targeted chimeric antigen receptor T cell therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis in a late breaking oral presentation at the 27th Annual Meeting of The American Society of Gene and Cell Therapy in Baltimore, MD. All patients were relapsed/refractory to standards-of-care Dara-CyBorD. At the NXC-201 ASGCT 2024 late-breaking oral presentation, data were presented from 13 relapsed/refractory AL amyloidosis patients in the ongoing Phase 1b/2a NEXICART-1 study. Patients were infused with CAR+T cells at doses of 150 x 106, 450 x 106, and 800 x 106. Patient characteristics: 85% had cardiac involvement; 38% had New York Heart Association stage 3 or 4 heart failure; 38% had Mayo stage 3 AL amyloidosis disease; Relapsed/refractory to a median 4 lines of prior therapyl 1 patient, patient 11, was treated and progressed on a BCMA-targeted bispecific antibody before NXC-201 treatment. Safety and efficacy data: Overall response rate of 92% for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201, of which 9 out of 12 were complete responders; 1 patient with prior exposure to BCMA-targeted bispecific treatment did not respond; Best responder had a duration of response of 28.0 months as of May 10, 2024, with response ongoing; There were no immune effector cell-associated neurotoxicity syndrome events; Median cytokine release syndrome duration was 2 days: No grade 4 CRS events; 2 experienced no CRS; 3 experienced grade 1 CRS; 6 Experienced grade 2 CRS; 2 experienced grade 3 CRS.